{
    "patient": {
        "Name": "James Hayes",
        "DateOfBirth": "1957-03-17",
        "Sex": "Male",
        "Diagnosis": "Invasive ductal carcinoma",
        "BodyPart": "Breast",
        "Physician": "Dr. Terri Francis",
        "TreatingInstitution": "Ho-Jackson"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Breast",
            "CollectedDate": "2024-04-16",
            "ReceivedDate": "2024-04-16",
            "TumorPercentage": "85%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-04-17",
            "ReceivedDate": "2024-04-19"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "KIT",
                "DNA Alteration": "c.2464A>T",
                "GeneMutation": "p.K818Q Frameshift-LOF",
                "VariantAlleleFraction": "3.21%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Stopgain-LOF",
                "VariantAlleleFraction": "7.95%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Stopgain-LOF",
                "VariantAlleleFraction": "1.69%"
            },
            {
                "Gene": "SIX1",
                "DNA Alteration": "c.530A>G",
                "GeneMutation": "p.G12S Frameshift-GOF",
                "VariantAlleleFraction": "17.8%"
            },
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.1144T>C",
                "GeneMutation": "p.C382R Nonsense-GOF",
                "VariantAlleleFraction": "8.51%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "PKLR",
            "FGFR3",
            "PRKCA",
            "HDAC1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "28 m/Mb",
            "Tmbpercentile": "81%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "MET",
                "DNA Alteration": "c.1510G>C",
                "GeneMutation": "p.S1236R Frameshift-LOF",
                "VariantAlleleFraction": "1.71%"
            },
            {
                "Gene": "HBA2",
                "DNA Alteration": "c.427T>C",
                "GeneMutation": "p.*143Qext*31 Nonsense-GOF",
                "VariantAlleleFraction": "16.91%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.8%"
            },
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Spliceregionvariant-LOF",
                "VariantAlleleFraction": "8.76%"
            },
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Spliceregionvariant-LOF",
                "VariantAlleleFraction": "1.86%"
            },
            {
                "Gene": "PDGFRB",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.T681I Frameshift-LOF",
                "VariantAlleleFraction": "8.15%"
            },
            {
                "Gene": "PAX5",
                "DNA Alteration": "c.239C>G",
                "GeneMutation": "p.A322T Stopgain-LOF",
                "VariantAlleleFraction": "7.15%"
            },
            {
                "Gene": "HBA2",
                "DNA Alteration": "c.427T>C",
                "GeneMutation": "p.*143Qext*31 Nonsense-LOF",
                "VariantAlleleFraction": "8.7%"
            }
        ],
        "Germline": [
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Nonsense-GOF",
                "Condition": "leg"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Frameshift-LOF",
                "Condition": "cell"
            }
        ]
    },
    "low coverage regions": [
        "RNF43",
        "AKT1"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "KIT",
                "DNA Alteration": "c.2464A>T",
                "GeneMutation": "p.K818Q Frameshift-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "3.21%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Stopgain-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "7.95%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Stopgain-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "1.69%"
            },
            {
                "Gene": "SIX1",
                "DNA Alteration": "c.530A>G",
                "GeneMutation": "p.G12S Frameshift-GOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "17.8%"
            },
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.1144T>C",
                "GeneMutation": "p.C382R Nonsense-GOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "8.51%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-04-14"
    },
    "other": {
        "ReportId": "6354",
        "ReportDate": "2024-04-19",
        "SignedBy": "Terri Francis",
        "Supervisor": "Dr. Angela Thornton"
    }
}